19 Feb 2021 12:52
GlaxoSmithKline plc (the 'Company')
Â
Transaction notification
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms V Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') Â ISIN: GB0009252882 Â Â Â Â | |||
b) | Nature of the transaction | Transfer of 10,726 Ordinary Shares between accounts for nil consideration. Â | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £0.00 | 10,726 |  | ||
 |  |  |  | ||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-02-16 | |||
f) | Place of the transaction  | N/A |
 Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms V Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') Â ISIN: GB0009252882 Â Â Â Â | |||
b) | Nature of the transaction | Transfer of 10,870 Ordinary Shares to spouse for nil consideration. Â Â | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £0.00 | 10,870 |  | ||
 |  |  |  | ||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-02-18 | |||
f) | Place of the transaction  | N/A |
Â
Â
 | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr I Whyte | |||
b) | Position/status | PCA of Ms V Whyte (Company Secretary) | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial  instrument | Ordinary shares of 25 pence each ('Ordinary Shares')  ISIN: GB0009252882     | |||
b) | Nature of the transaction | Receipt of 10,870 Ordinary Shares from spouse for nil consideration. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £0.00 | 10,870 |  | ||
 |  |  |  | ||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-02-18 | |||
f) | Place of the transaction  | N/A |
Â
Â
Â
Â
Â
Â
Â
Â
Â
Â
Â